FOSUN PHARMA's Flurbiprofen Axetil Injection Receives Marketing Authorization

Stock News17:44

FOSUN PHARMA (02196) has announced that its subsidiary, Chongqing Yaoyou Pharmaceutical Co., Ltd., recently obtained approval from the National Medical Products Administration for the drug registration of Flurbiprofen Axetil Injection. The approved indication is for postoperative and cancer pain management. This drug is a chemically synthesized product independently developed by the group. As of March 2026, the group's cumulative R&D investment in this drug amounted to approximately RMB 34 million (unaudited). According to the latest data from IQVIA CHPA, the sales of Flurbiprofen Axetil Injection in China (excluding Hong Kong, Macao, and Taiwan) reached about RMB 1.158 billion in 2025.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1173461200?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-04-10 17:44","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1173461200","market":"other","top_or_hot":-1,"title":"FOSUN PHARMA's Flurbiprofen Axetil Injection Receives Marketing Authorization","media":"Stock News","content":"<p>FOSUN PHARMA (02196) has announced that its subsidiary, Chongqing Yaoyou Pharmaceutical Co., Ltd., recently obtained approval from the National Medical Products Administration for the drug registration of Flurbiprofen Axetil Injection. The approved indication is for postoperative and cancer pain management. This drug is a chemically synthesized product independently developed by the group. As of March 2026, the group's cumulative R&D investment in this drug amounted to approximately RMB 34 million (unaudited). According to the latest data from IQVIA CHPA, the sales of Flurbiprofen Axetil Injection in China (excluding Hong Kong, Macao, and Taiwan) reached about RMB 1.158 billion in 2025.</p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>FOSUN PHARMA's Flurbiprofen Axetil Injection Receives Marketing Authorization</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nFOSUN PHARMA's Flurbiprofen Axetil Injection Receives Marketing Authorization\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1036600163\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock News </p>\n<p class=\"h-time\">2026-04-10 17:44</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>FOSUN PHARMA (02196) has announced that its subsidiary, Chongqing Yaoyou Pharmaceutical Co., Ltd., recently obtained approval from the National Medical Products Administration for the drug registration of Flurbiprofen Axetil Injection. The approved indication is for postoperative and cancer pain management. This drug is a chemically synthesized product independently developed by the group. As of March 2026, the group's cumulative R&D investment in this drug amounted to approximately RMB 34 million (unaudited). According to the latest data from IQVIA CHPA, the sales of Flurbiprofen Axetil Injection in China (excluding Hong Kong, Macao, and Taiwan) reached about RMB 1.158 billion in 2025.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"02196","symbol_name":"复星医药","start_time":0,"source_url":"","article_id":"1173461200","we_media_id":"1036600163","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1173461200","pubTimestamp":1775814265,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Stock News","introduction":"Global Stock News First-Time Broadcast","home_visible":1,"id":"1036600163","head_image":"https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a"},"summary":"FOSUN PHARMA (02196) has announced that its subsidiary, Chongqing Yaoyou Pharmaceutical Co., Ltd., recently obtained approval from the National Medical Products Administration for the drug...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"600196":"复星医药","02196":"复星医药","BK0183":"MSCI概念","BK1515":"抗疫概念","BK0188":"融资融券","BK0096":"民营医院","BK1593":"医美概念股","BK1191":"制药","BK0012":"证金概念","BK0196":"行业龙头","BK0175":"白马股","BK0187":"一线龙头","BK0060":"抗癌","BK0028":"国家队","BK0239":"医药制造"},"translate_title":"复星医药氟比洛芬酯注射液获上市许可","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"600196":1,"02196":1},"content_text":"FOSUN PHARMA (02196) has announced that its subsidiary, Chongqing Yaoyou Pharmaceutical Co., Ltd., recently obtained approval from the National Medical Products Administration for the drug registration of Flurbiprofen Axetil Injection. The approved indication is for postoperative and cancer pain management. This drug is a chemically synthesized product independently developed by the group. As of March 2026, the group's cumulative R&D investment in this drug amounted to approximately RMB 34 million (unaudited). According to the latest data from IQVIA CHPA, the sales of Flurbiprofen Axetil Injection in China (excluding Hong Kong, Macao, and Taiwan) reached about RMB 1.158 billion in 2025.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"productRelease","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":1,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.40.0","shortVersion":"4.40.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1173461200","isCrawlerRequest":true}